India approves phase-3 trial of Covid-19 vaccine Corbevax
Already armed with four fully-approved Covid-19 vaccines, the Drugs Controller General of India (DCGI) has approved the phase-three human trial of yet another vaccine, Corbevax, by private pharma major Biological E's for adults, children and adolescents.
The approval was given after the government's Subject Expert Committee (SEC) reviewed Phase one and two clinical trial data of the proposed vaccine called "Corbevax", the Science and Technology Ministry said today, according to our New Delhi correspondent.
The trials will evaluate the safety, reactogenicity, tolerability and immunogenicity of the "Corbevax" vaccine.
Once cleared after the human trials, "Corbevax", whose development has been funded by the Indian government, will be the fifth vaccine in India which already has four, Covishield, Covaxin, Sputnik V and Moderna.
India hopes to market vaccines for children and teachers by this month as schools and colleges have started resuming physical classes.
The government's Department of Biotechnology (DBT) under the Ministry of Science and Technology has taken initiatives to increase investments in research and development and manufacturing of Covid-19 vaccines.
Three more vaccines in the pipeline are Zydus Cadila's DNA-based vaccine, another jab from Gennova, which is an mRNA vaccine and Novavax which will be manufactured by the Serum Institute of India.
Comments